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Parathyroid hormone (PTH), PTH-derived peptides, and new Reliable measurements of the concentration of para-
PTH assays in renal osteodystrophy. Reliable measurements thyroid hormone (PTH) in serum or plasma are essential
of parathyroid hormone (PTH) concentrations in serum or for the effective clinical management of patients withplasma are critical for the appropriate diagnosis and manage-
chronic renal failure. Metabolic bone disease is commonment of patients with renal osteodystrophy. With the introduc-
in such patients [1, 2], and most available evidence indi-tion of second generation immunometric assays for PTH, it is
now possible to measure exclusively full-length, biologically cates that PTH is the major determinant of the rates of
active PTH(1-84). In contrast, first generation immunometric bone remodeling and turnover in those with end-stage
assays that have been used widely for many years detect not renal disease (ESRD) [3]. Plasma PTH concentrations,only PTH(1-84), but also other large amino-terminally-trun-
which predominantly reflect basal rates of PTH releasecated, PTH-derived peptides. This development will require a
from the parathyroid glands [4], largely determine whe-careful re-evaluation of PTH measurements, as determined by
either first or second generation immunometric assays, and ther patients with ESRD develop high-turnover skeletal
their relationship to bone histology and bone remodeling rates lesions of renal osteodystrophy due to secondary hyper-
in patients with end-stage renal disease (ESRD). Such informa-
parathyroidism or low-turnover lesions such as adynamiction is essential for proper clinical management, but only lim-
bone [1, 2, 5, 6]. Accurate assessments of plasma PTHited bone biopsy data are available to guide the interpretation
of PTH results using second generation PTH assays. The differ- levels thus are essential not only for the proper labora-
ent performance characteristics of first and second generation tory diagnosis of renal bone disease but also to appropri-
immunometic PTH assays also makes it possible to quantify ately monitor evolution of the disorder, particularly dur-
the plasma levels of amino-terminally-truncated, PTH-derived
ing the treatment of secondary hyperparathyroidism withpeptides, which may accumulate disproportionately in patients
active vitamin D sterols [2].with ESRD. Recent experimental evidence indicates that one
or more of these peptides can modify bone cell activity and skel- Several developments in recent years have served to
etal remodeling, possibly by interacting with a PTH receptor challenge prevailing concepts about the value of PTH
distinct from the type I PTH receptor that binds to the amino- measurements in patients undergoing regular dialysis.
terminal portion of PTH and mediates the classical biological
Among these was the observation that bone formation,actions of the hormone. The putative C-PTH receptor interacts
as measured by the technique of double-tetracycline la-with mid- and/or carboxyterminal regions of PTH and other
amino-terminally-truncated PTH-derived peptides; signaling beling in iliac crest bone biopsies, decreased dramatically
through it may contribute to the skeletal resistance to PTH in some patients with secondary hyperparathyroidism
that characterizes ESRD. The current review discusses certain after treatment with large intermittent doses of calcitriol,
aspects of the molecular structure of PTH and its interaction
or 1,25-dihydroxyvitamin D3 [7, 8]. Such findings suggestedwith various receptors, briefly comments about selected com-
that plasma PTH levels may not accurately reflect boneponents of PTH secretion, highlights recent technical advances
in PTH assays, and summarizes the effects of various PTH- formation and turnover, and ultimately bone histology,
derived peptides on bone cells and on skeletal metabolism. during intermittent calcitriol therapy. Similar changes
also might occur during treatment with new vitamin D
sterols such as paricalcitol (Zemplar) or doxercalciferol
Key words: immunometric PTH assay, clinical management, end-stage
(Hectorol), but data that address this issue have yet torenal disease, peptides and bone cells, chronic renal failure, skeletal
lesions, PTH(1-84), renal bone disease. be reported.
Other work has questioned the validity of serum or
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sion of study participants and methodological issues or for monitoring progression of the disorder in patients
with ESRD.probably account for certain disparities among published
reports. It should be recognized, however, that much of Recent work aimed at defining the molecular mecha-
nisms responsible for the biological actions of PTH andthe information that documents the relationship between
serum or plasma PTH levels and bone histology in pa- other PTH-related peptides in bone and other target
tissues provides important new information that is rele-tients with ESRD was collected more than 15 years ago
[1, 6, 10–14]. Although the results continue to guide cur- vant to understanding bone metabolism and skeletal re-
modeling in chronic renal failure. The goal of the currentrent diagnostic and therapeutic decisions, the data were
obtained when therapeutic approaches to secondary hyper- discussion is to review various issues pertaining to the
molecular structure of PTH and its interactions withparathyroidism differed substantially from those em-
ployed currently. They largely represent findings in un- various receptors, to briefly discuss selected components
of PTH secretion, to summarize technical advances intreated patients and those managed with small daily oral
doses of calcitriol, whereas large thrice-weekly intrave- methods for determining the concentration of PTH in
biological samples, and to examine the physiological ef-nous doses of calcitriol and other vitamin D sterols now
are widely used to treat secondary hyperparathyroidism fects of various PTH-derived peptides on bone cells and
their potential role as modifiers of skeletal metabolism.[15–18]. Moreover, many of the patients in older studies
received aluminum-containing, phosphate-binding med- The integration of this information into current knowl-
edge about bone and mineral metabolism in chronic re-ications rather than large oral doses of calcium. Intermit-
tent calcitriol therapy and high oral calcium intakes have nal failure may provide a broader fundamental under-
standing of renal bone disease.each been cited as causes for the evolving histological
pattern of renal bone disease in recent years and for the
relatively higher prevalence of adynamic renal osteodys-
THE MOLECULAR STRUCTURE OF PTH AND
trophy in the contemporary dialysis population [1, 2, 19].
PTH RECEPTORS
Beyond these historical developments, new PTH as-
Parathyroid hormone (PTH) is a peptide comprised ofsays have been introduced, and it is now generally recog-
84 amino acids [25, 26]. It initiates signal transduction innized that several widely utilized PTH assays cross-react
a variety of tissues by binding to the type I PTH (PTH1)with and detect peptide fragments that are distinct from
receptor, accounting for most of the classical biologicalfull length, biologically active PTH, or PTH(1-84) (vide
actions of PTH [27]. The PTH1 receptor also is knowninfra) [20–23]. Awareness of these technical advances
as the common receptor for PTH and PTH-related pep-has been spread through scientific meetings and by com-
tide, or PTHrP, because it binds to and initiates signalmercial endorsements. Certain proprietary claims appear
transduction events in response to both PTH and PTHrPpremature, however, and have not been documented ade-
(Fig. 1) [27].quately. In this regard, it has been suggested that mea-
The binding of PTH to its receptor is mediated by thesurements of the concentration of amino-terminally-trun-
amino-terminal, or N-terminal, portion of the peptide [28].cated PTH-derived peptides, or other PTH fragments,
This is also the case for PTHrP, a larger peptide hormonein serum or plasma are useful for the diagnosis of renal
that appears as three isoforms comprised of 139, 141 orbone disease [24]. This issue deserves careful and objec-
171 amino acids [29]. Excess production of PTHrP bytive scrutiny.
various tumors is usually responsible for the syndromeThese striking developments have generated uncer-
of humoral hypercalcemia of malignancy [29].tainty and considerable confusion among clinicians about
The N-terminal portions of PTH and PTHrP are iden-the pathophysiology, diagnosis, and appropriate man-
tical for eight of their first 13 N-terminal amino acidagement of renal bone disease. In this context, it should
residues [29], and the two peptides are equivalent inbe recognized that few studies have been done using new
activating the PTH1 receptor [27]. Recent efforts havePTH assays to assess disorders of bone and mineral me-
documented the importance of several key sites withintabolism in patients with ESRD, and there is a paucity
the first 34 N-terminal amino acids of PTH that areof data to guide the interpretation of results. Indeed, only
involved in high-affinity interactions with the PTH1 re-limited information is available about the relationship
ceptor, some of which are crucial for receptor activation,between plasma PTH levels, as determined by any of sev-
probably by mediating conformational changes in theeral new PTH assays, and the various subtypes of renal
receptor protein. Thus, PTH binds to both the extracellu-osteodystrophy, as documented by bone biopsy (abstract;
lar, N-terminal domain and to extracellular loops withinSalusky et al, J Am Soc Nephrol 12:772A, 2001) [24].
the membrane spanning portion of the PTH1 receptorIt is not yet therefore known whether the information
[30, 31]. Modifications in the amino acid composition ofprovided by new PTH assays will prove to be superior
the N-terminal portion of PTH(1-84) or deletions at theto that available using current assay methods either for
the initial laboratory diagnosis of renal osteodystrophy amino-terminus of the molecule substantially diminish
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Fig. 1. Depiction of two distinct cellular re-
ceptors for parathyroid hormone (PTH). The
PTH1 receptor mediates most of the classical
biological actions of full-length PTH(1-84) in
target tissues by initiating intracellular signal
transduction through protein kinase A and pro-
tein kinase C. The amino-terminal domains of
both PTH and parathyroid hormone-related
peptide (PTHrP) bind with equal affinity to the
PTH1 receptor. In contrast, the putative C-PTH
receptor interacts with portions of PTH that are
located further toward the mid- and carboxy-
terminal regions of the peptide. The C-PTH re-
ceptor binds to several amino terminally trun-
cated PTH-derived peptides including PTH
(7-84), but signal transduction pathways for the
C-PTH receptor have yet to be characterized.
binding to the PTH1 receptor [28]. In contrast, trunca- and/or C-terminal regions of PTH [43–47]. In recent dis-
cussions, this putative receptor, which has yet to be cloned,tions at the carboxy-terminal, or C-terminal, end of PTH
(1-84) do not affect receptor affinity. Therefore, both has been called the C-PTH receptor (Fig. 1). In clonal
osteoblast-like cells, high affinity radioligand bindingPTH(1-34) and PTH(1-84) exhibit equal ligand binding
affinity for the PTH1 receptor (Fig. 1). could be demonstrated for recombinant analogs of hu-
man PTH such as [Tyr34]hPTH(1-84) and [Tyr34]hPTHIn addition to the PTH1 receptor, two other PTH
receptors have been identified and cloned. The PTH2 (19-84), whereas neither ligand bound with high affinity
to LLCPK1 cells that stably expressed the recombinantreceptor was originally isolated from cDNA libraries
from cerebral cortex [32]. It is expressed predominantly PTH1 receptor [47]. In addition, high-affinity radioligand
binding to ROS17/2.8 osteoblast-like cells and to osteocy-in the central nervous system, pancreas, testis and pla-
centa. The PTH2 receptor appears to be more ligand- tic cells was reduced by the addition of increasing amounts
of several unlabeled C-terminal fragments of PTH(1-84),specific than the PTH1 receptor. Whereas the N terminal
domains of PTH and PTHrP both bind to and initiate but not by synthetic PTH(1-34) [47]. Such findings pro-
vide firm experimental evidence that bone cells of the os-signal transduction through the PTH1 receptor, PTH2
receptors from several species are activated only poorly teoblastic lineage have a distinct PTH receptor that inter-
acts with the mid- or carboxy-terminal regions of PTH.or not at all by PTH or PTHrP [33]. Only the human
PTH2 receptor is efficiently activated by PTH [32, 34]. The potential functional relevance of the C-PTH re-
ceptor as a modulator of bone cell activity has beenRecent studies suggest that a 39 amino-acid peptide, tu-
beroinfundibular protein (TIP39), is most likely the natu- examined both in vivo and in vitro. Nguyen-Yamamoto
and co-workers reported that intravenous infusions ofral ligand for the PTH2 receptor [35]. This peptide was
initially isolated from bovine hypothalamus and shows synthetic PTH(7-84) and other N-terminally-truncated
PTH peptides, including PTH(39-84) and PTH(53-84),some distant homology to PTH and PTHrP [35, 36].
Interestingly, TIP39 and truncated analogs of it can bind counteract the effects of PTH(1-84) and PTH(1-34) to
raise blood ionized calcium concentrations in thyro-para-to the PTH1 receptor, raising the possibility that it may
act as an inhibitor of PTH or PTHrP actions [37, 38]. thyroidectomized rats [48]. Qualitatively similar, but less
complete, results were presented earlier by SlatopolskyThe functional role(s) of the PTH2 receptor remain un-
certain, but there is evidence that it may be involved in et al [49]. Nguyen-Yamamoto and co-workers also dem-
onstrated that synthetic PTH(1-84) and PTH(7-84) bothpain perception [39]. A third receptor, the PTH3 recep-
tor, has been identified only in zebrafish [40, 41]. PTH bind specifically to the putative C-PTH receptor, whereas
PTH(1-34) does not, findings consistent with earlier ex-and PTHrP each bind with similarly high efficiency to
the zebrafish PTH3 receptor, but it is not activated by perimental observations [48]. Conversely, both PTH(1-84)
and PTH(1-34) were shown to bind to the PTH1 receptorTIP39 [42].
More pertinent to recent discussions about the bio- and increase cyclic adenosine 3,5-monophosphate AMP
(cAMP) levels in ROS 17/2.8 cells, whereas PTH(7-84)logical actions of PTH in renal failure are data reported
originally many years ago but that have been character- failed to effectively compete for binding to the PTH1 re-
ceptor or generate a cAMP response. Interestingly, cAMPized in greater detail more recently to suggest the exis-
tence of a distinct PTH receptor that interacts with mid- generation was greater during incubations with PTH
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(1-34) than with PTH(1-84) at equimolar concentrations iations in blood calcium levels. At reduced blood ionized
calcium concentrations, PTH(1-84) appears to be thein ROS 17/2.8 cells [48]. These latter results are consis-
tent with the view that binding of the mid- or C-terminal predominant form of PTH secreted by the parathyroid
glands and is the major species of PTH found in periph-portions of PTH(1-84) to the C-PTH receptor modulates,
or partially offsets, the agonist actions of PTH(1-84) that eral blood when measured using assays that detect the
N terminal portion of the molecule; lesser amounts ofare mediated through the PTH1 receptor (Fig. 1).
Divieti et al provided additional evidence that signal- N-terminally-truncated, PTH-derived peptides, or carboxy-
terminal PTH fragments, are detected [54, 56]. In con-ing through the C-PTH receptor can influence bone me-
tabolism in vitro [50]. Incubations with human PTH(7-84) trast, relatively greater amounts of C-terminal PTH frag-
ments are present in the circulation, as assessed by assaydiminished 45Ca release from pre-labeled neonatal mouse
calvariae and also reduced in vitro bone resorption in- systems that cross-react with carboxy-terminal portions
of the PTH molecule, when blood ionized calcium con-duced by several agents including human PTH(1-84),
PTH(1-34), 1,25-dihydroxyvitamin D3, prostaglandin E2 centrations are elevated [56]. It remains uncertain whe-
ther these changes reflect variations in the metabolism(PGE2), and interleukin-11 (IL-11). Moreover, both syn-
thetic human PTH(7-84) and PTH(39-84) impaired the of PTH within parathyroid cells, alterations in the degra-
dation of PTH in peripheral tissues, or the aggregate re-formation of osteoclast-like cells in response to 1,25-dihy-
droxyvitamin D3 in murine bone marrow cultures [50]. sult of both processes. Although calcium-regulated PTH
secretion by parathyroid cells is mediated by the calcium-Because osteoclastic bone resorption that is initiated by
agents such as PTH, 1,25-dihydroxyvitamin D3, PGE2 sensing receptor (CaSR) [57], the role of CaSR activa-
tion as a modifier of intracellular PTH degradation isand IL-11 is modulated by RANKL and osteoprotegerin
(OPG) [51], it is plausible that the inhibitory actions of not known. Similarly, treatment with vitamin D dimin-
ishes pre-pro-PTH gene transcription [58, 59], but littlePTH analogs such as PTH(7-84) or PTH(39-84) on osteo-
clastogenesis are mediated by variations in RANKL or is known about direct effects of vitamin D on PTH me-
tabolism. Vitamin D-mediated increases in serum cal-OPG expression. Direct effects of C-terminal PTH frag-
ments on osteoclasts or osteoclast-precursors cannot, how- cium concentrations would be expected, however, to in-
fluence the metabolism of PTH as discussed previously.ever, be excluded. Thus, N-terminally-truncated PTH-
derived peptides appear not only to influence osteoblastic The release of abundant amounts of full length, biolog-
ically active PTH(1-84), and lesser amounts of C-termi-function but also to affect osteoclastic differentiation and
bone resorption by signaling through a C-PTH receptor. nal PTH fragments from the parathyroid glands, under
conditions of hypocalcemia, theoretically, would max-High levels of C-PTH receptor expression in osteocytes
in vitro suggest an additional cellular target for N-termi- imize biological responses mediated by PTH1 receptors
located in kidney and bone, serving to restore serumnally-truncated PTH-derived peptides in bone [52].
The existence of a C-PTH receptor suggests a potential calcium concentrations to normal. Conversely, the re-
lease of relatively greater amounts of C-terminal PTHmechanism to account for recent observations in several
experimental models (Fig. 1). Considerable additional fragments, as PTH(1-84) levels decline under conditions
of hypercalcemia, could confer an additional level ofwork will be required, however, to adequately document
the clinical relevance of these findings to the regulation of regulatory control over serum calcium concentrations
if N-terminally-truncated PTH-derived peptides such asskeletal metabolism in humans with renal osteodystrophy.
PTH(7-84) or PTH(19-84) indeed modulate the agonist
actions of PTH(1-84) [48, 49]. Although preliminary dataCALCIUM-MEDIATED PTH SECRETION AND
support this possibility, formal experimental confirma-ITS EFFECT ON THE SPECIES OF PTH IN
tion is needed to determine whether variations in thePERIPHERAL BLOOD
species of PTH in the circulation participate in the regu-
It is generally thought that PTH is released from para- lation of serum calcium concentrations by influencing
thyroid cells predominantly as the full length biologically calcium fluxes in kidney and/or bone.
active hormone, PTH(1-84). PTH that is stored within
secretory granules can be degraded, however, within the
METHODS FOR MEASURING THEcell, particularly in the presence of high extracellular
CONCENTRATION OF PTH IN SERUMcalcium concentrations, and some of these peptide frag-
OR PLASMAments gain access to the circulation [53, 54]. PTH(1-84)
also undergoes metabolism in peripheral tissues, most Adequate control of secondary hyperparathyroidism
is important in managing bone disease in patients withnotably liver [55]. Thus, PTH-derived peptides other
than PTH(1-84) are present in peripheral blood [20, 56]. ESRD. Histopathology is the definitive method for docu-
menting various forms of renal osteodystrophy, but boneThe relative amounts of PTH(1-84) and other PTH-
derived peptides in serum or plasma are affected by var- biopsy is an invasive diagnostic procedure and relatively
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Fig. 2. A comparison of technical aspects of
first and second generation immunometric as-
says for PTH. Both methods employ capture
antibodies directed toward epitopes located
within the carboxyterminal region of the pep-
tide to immobilize labeled hormone on a solid
phase. Detection antibodies are targeted to epi-
topes located closer to the amino-terminal end
of the peptide. In first generation immuno-
metric PTH assays, detection antibodies were
directed, most probably, to a region between
amino acid residues 15 and 34. By contrast,
detection antibodies in second generation im-
munometric PTH assays are directed toward
epitopes in the most amino-terminal portion
of the molecule. Synthetic PTH peptides that
are truncated at their amino-terminal end such
as PTH(2-34), PTH(3-34) and PTH(7-84) are
not detected in second generation assays, but
cross-react with the detection antibodies used
in first generation assays.
few laboratories have the expertise and equipment needed peptides, presumably full length intact PTH(1-84), min-
imizing cross-reactivity with smaller PTH fragments.to do bone histomorphometry. Thus, clinicians rely al-
most exclusively upon plasma or serum PTH determina- Technically, one antibody, which is directed toward an
epitope located in the C-terminal region of PTH, is at-tions to guide clinical management.
Assays for PTH that were developed during the 1960s, tached to a solid phase, such as a plastic bead, and serves
to capture the hormone in serum or plasma (Fig. 2).1970s and 1980s employed conventional radioimmunoas-
say (RIA) techniques [60, 61]. Here, isotopically labeled A second antibody, directed at an epitope within the
N-terminal region of PTH, is labeled, usually with 125Ipeptides, usually highly purified intact PTH or synthetic
PTH fragments, were used in competitive displacement or a chemiluminescent agent, and serves as the signaling
antibody (Fig. 2). Aliquots of serum or plasma containingassay systems to measure hormone concentrations in se-
rum or plasma. Because the most antigenic portions of unknown concentrations of PTH are incubated with both
antibodies, and the amount of the signaling antibodyPTH are located in the mid- and carboxy-terminal re-
gions of the molecule, virtually all RIAs for PTH de- that separates with the solid phase is then measured.
Relatively small peptide fragments that bind to eithertected a variety of carboxy-terminal PTH fragments in
addition to full-length, biologically active PTH(1-84). antibody alone are not detected in these assay systems
because a relatively long peptide is required to bridgeThese features posed serious problems for the interpre-
tation of results in patients with chronic renal failure. the space between the two epitopes located in different
regions of the PTH molecule (Fig. 2). Only peptides ofParathyroid hormone and various of its peptide frag-
ments are largely cleared from the circulation by glomer- sufficient length to bridge both epitopes within PTH and
thereby link the immobilized antibody to the labelingular filtration, and they undergo catabolism within tubu-
lar epithelial cells of the proximal nephron after uptake antibody are detected.
Until recently, first generation immunometric PTHvia megalin-dependent mechanisms [62, 63]. In patients
with end-stage renal disease, fragments of PTH accumu- assays were thought to detect either predominantly or
exclusively full length PTH(1-84). It is now evident, how-late in plasma and are found in high concentrations. Since
many of these fragments cross-reacted with antibodies ever, that this is not the case. First generation immuno-
metric PTH assays cross-react with other large amino-used in various PTH RIAs, serum PTH values deter-
mined by these assays were frequently markedly elevated terminally-truncated PTH-derived peptides, some of which
co-elute on high-performance liquid chromatographyin patients with chronic renal failure, measurements were
often unreliable, and results corresponded poorly to his- (HPLC) with synthetic PTH(7-84) [20, 21]. It is likely
that other PTH-derived peptides also are present in serumtological findings documented by bone biopsy [12, 64].
Many of the technical shortcomings of RIAs for PTH or plasma, particularly in patients with ESRD. By con-
trast, recently introduced second generation immuno-were overcome with the introduction of immunometric
assays [65], which were originally called immunoradio- metric PTH assays detect PTH(1-84) exclusively [22, 23,
49]. They do not cross-react with synthetic PTH(7-84) ormetric assays, or IRMAs, because they used a radioiso-
tope to label detection antibodies. These systems employ other peptide fragments that lack the first few N-terminal
amino acids of PTH(1-84) (Fig. 2) [22].two antibodies in a “sandwich” type assay to detect longer
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For second generation immunometric PTH assays, from a rather heterogeneous population that included
both hemodialysis and peritoneal dialysis patients, thosespecificity for PTH(1-84) is determined by a labeling
antibody that is directed toward an epitope located given daily oral doses or intravenous doses of calcitriol,
and untreated patients [9].within the most N-terminal portion of the molecule. Syn-
thetic peptides that have been truncated at the N termi- Bone biopsy information is just now beginning to be
collected in ESRD patients who have been assessed us-nal end such as PTH(7-84) are not detected because the
epitope is either absent or structurally altered. Indeed, ing second generation immunometric PTH assays (ab-
stract; Salusky et al, ibid) [24]. Considerable additionaldeletion of only the first amino acid from synthetic
PTH(1-34) is sufficient to eliminate cross-reactivity of work is needed to establish the relationship between
plasma PTH levels, as measured by second generationthe peptide with the detection antibody used in certain
second generation immunometric PTH assays [22]. In immunometric PTH assays, and the various subtypes of
renal osteodystrophy not only in untreated patients, butcontrast, detection antibodies used in first generation
immunometric PTH assays were directed toward epi- also in those who are treated with active vitamin D ste-
rols. To date, there is insufficient information to guidetopes located more distally within the amino-terminal
portion of the PTH molecule, probably between amino diagnostic and therapeutic decisions about renal osteo-
dystrophy using new PTH assays due to the paucity ofacid residues 15 and 34. As such, first generation immu-
nometric PTH assays were fully capable of detecting bone histology data.
In this regard, a recent report presents bone histomor-N-terminally-truncated PTH fragments such as PTH(7-84)
as well as full length PTH(1-84) (Fig. 2) [22, 23]. phometric data and corresponding PTH results using both
first and second generation immunometric PTH assays inWhen measured by second generation immunometric
PTH assays, plasma PTH concentrations are approxi- 51 patients with ESRD [24]. The relationships between
plasma PTH levels and bone remodeling, as measured bymately 40 to 50% lower than values obtained using first
generation immunometric assays both in subjects with the histomorphometric parameter activation frequency,
were similar with each assay. Neither assay was superiornormal renal function and in those with end-stage renal
to the other in distinguishing between patients with ady-disease [22–24, 49]. Despite such differences, several
namic renal osteodystrophy and those with normal or highstudies, some of which have been published, demonstrate
rates of bone turnover as documented by bone biopsy [24].a high degree of correlation across a wide range of PTH
However, the authors took advantage of technical dif-concentrations between the results obtained with first
ferences between the two assays to estimate the concen-and second generation immunometric PTH assays when
tration of N terminally-truncated PTH-derived peptidemeasurements are done using both methods in the same
fragments in plasma. Based upon in vitro and in vivoplasma samples [22, 23].
experimental work mentioned previously, there is evi-
dence to suggest that one or more N terminally-trun-
PTH AND BONE METABOLISM IN cated, PTH-derived peptides exert inhibitory effects on
RENAL FAILURE osteoblasts and on bone remodeling. To address this issue,
As noted previously, virtually all of the available data the concentration of PTH fragments [PTH(frag)] in
about the relationship between plasma PTH levels and plasma was estimated by subtracting PTH values deter-
bone histopathology in patients with renal osteodystro- mined using a second generation immunometric PTH
phy have been generated using first generation immuno- assay, which detects PTH(1-84) exclusively, from values
metric PTH assays or older RIAs. Values determined obtained using a first generation immunometric PTH
by first generation immunometric PTH assays generally assay that detects both PTH(1-84) and other relatively
predict the underling type of renal bone disease in un- large N terminally-truncated PTH-derived fragments. A
treated patients and in those receiving small daily oral ratio depicting the relative abundance of biologically ac-
doses of vitamin D, specifically calcitriol [1, 14, 19, 66–68]. tive PTH(1-84) to the amount of PTH fragments also was
Published results are somewhat dated, however, and they calculated and expressed as PTH(1-84)/PTH(frag) [24].
may not accurately reflect the impact of current therapeu- Overall, patients with adynamic renal osteodystrophy
tic practices, which often include the use of large, intermit- had lower PTH(1-84)/PTH(frag) ratios than those with
tent intravenous doses of vitamin D sterols and large either normal or high rates of bone turnover, and none
oral doses of calcium. Both interventions appear to dis- of the patients with adynamic bone had a PTH(1-84)/
rupt the relationship between plasma PTH levels and PTH(frag) ratio that exceeded unity. Thus, there appears
bone turnover, perhaps through direct inhibitory effects to be a relative abundance of N terminally-truncated
on osteoblasts [7, 8, 69–71]. Although some reports have PTH fragments compared to PTH(1-84) in patients with
questioned the diagnostic utility of first generation im- ESRD who have subnormal rates of bone turnover. It
munometric PTH assays to assess renal osteodystrophy should be noted, however, that some patients with hyper-
parathyroid bone disease also had PTH(1-84)/PTH(frag)in patients with ESRD, the results reflect data obtained
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ratios1. As such, a calculated PTH(1-84)/PTH(frag) ra- viously reported data from other bone histology labora-
tories in patients with renal bone disease [24]. Recenttio 1 was not diagnostic of adynamic bone [24]. Never-
theless, the results were taken as evidence that N termi- observations indicate that activation frequency does not
offer additional information beyond that provided bynally-truncated, PTH-derived peptides have inhibitory
effects on bone remodeling in patients with ESRD and measurements of bone formation, and there are method-
ological issues with determining activation frequencythat their accumulation in plasma accounts for the devel-
opment of adynamic renal osteodystrophy. when bone formation rates are markedly reduced as in
adynamic renal osteodystrophy [72]. Additional assess-The hypothesis set forth by these investigators is an
interesting one, and it certainly warrants further inves- ments using conventional measures of bone formation
would be useful in future clinical studies to examine thetigation considering recent experimental observations.
If documented adequately in future studies, information putative inhibitory role of various PTH-derived peptides
in renal bone disease.about factors that influence the generation and relative
abundance of N terminally-truncated, PTH-derived pep- Apart from technical issues, matters of patient selec-
tion constrain the broad application of recent findings.tides could offer additional insight into mechanisms that
modulate osteoblastic activity and skeletal remodeling Although PTH is considered to be the major determinant
of bone formation and turnover in ESRD, other factorsin chronic renal failure. Several issues must be addressed,
however, in evaluating the clinical relevance of these also play a role [3]. Treatment with corticosteroids and
aluminum intoxication each diminish bone formation andfindings.
One concern relates to apparent discrepancies with turnover, whereas growth hormone administration not
only promotes linear growth, but also increases boneearlier reports about the relationship between PTH val-
ues obtained by two distinct immunometric PTH assays. formation during skeletal remodeling [2, 73–75]. Diabe-
tes mellitus can affect bone and mineral metabolism ad-In previous work, a high degree of correlation (r 0.977)
was shown between results obtained with the second gen- versely even when renal function remains normal [76].
eration immunometric PTH assay employed in the work Osteoblastic activity is reduced and bone formation is
by Monier-Faugere et al [24] and values determined us- subnormal in many diabetic subjects, and studies in ex-
ing a widely utilized first generation immunometric PTH perimental animals with diabetes indicate that insulin
assay in 318 patients with ESRD [23]. Similarly high deficiency is largely responsible for these disturbances,
coefficients of correlation have been found in other com- which are not explained adequately by decreases in plasma
parative studies of first and second generation immuno- PTH levels [77, 78].
metric PTH assays, documenting a relatively fixed linear Such observations in diabetic subjects are relevant to
relationship between values obtained with each method the current discussion of adynamic renal osteodystrophy
(abstract; Salusky et al, ibid) [49]. Because these correla- because about 25% of the adult patients with ESRD
tions are linear, there is a constant relationship, or ratio, who were evaluated by bone biopsy and concurrent esti-
as defined by the slope of the regression line, between mates of the PTH(1-84)/PTH(frag) ratio had diabetes [24].
PTH values measured by the two methods. Moreover, As such, a mechanism distinct from variations in the
since the concentration of N terminally-truncated, PTH- PTH(1-84)/PTH(frag) ratio could account for the pres-
derived peptides represents the simple numeric differ- ence of adynamic bone in many of the study participants.
ence between two highly correlated variables, the PTH A homogenous group of patients unaffected by factors
(1-84)/PTH(frag) ratio also, by definition, must remain capable of independently modifying bone metabolism is
fairly constant across the observed range of plasma PTH required to more precisely characterize the impact of
concentrations. In this context, it is difficult to under- various PTH(1-84)/PTH(frag) ratios on skeletal remod-
stand the wide variation in values for the PTH(1-84)/ eling in chronic renal failure. In this regard, estimates
PTH(frag) ratio reported in patients with ESRD, which of the relative abundance of PTH(1-84) and other amino-
ranged from 0.01 to 14.2 [24]. terminally truncated PTH fragments did not prove useful
The use of activation frequency as the sole histomor- in a recent report for identifying patients with adynamic
phometric index of bone remodeling in patients with renal osteodystrophy as documented by quantitative bone
ESRD presents additional problems [24]. Most clini- histomorphometry [79].
cians are unfamiliar with the term, how it is determined,
and what it means. Measurements of bone formation are
IMPLICATIONS OF RECENT DEVELOPMENTSmore familiar to a greater number of readers and they
FOR CLINICAL MANAGEMENTare better understood. Although not strictly a measure
While new developments intrigue investigators, theyof bone remodeling, bone formation provides a concise
frustrate clinicians. It is increasingly apparent that valuesobjective measure of one component of the tightly-cou-
determined using first generation immunometric PTHpled process of bone remodeling. Information about bone
formation also would facilitate comparisons with pre- assays are less reliable now than in the past as non-
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invasive indicators of renal osteodystrophy, probably as Caution is warranted, however, to avoid lowering plasma
PTH levels excessively in patients with secondary hyper-a result of evolving therapeutic practices.
Current guidelines suggest that plasma PTH levels, parathyroidism who are treated with active vitamin D
sterols. Reductions in the dose of vitamin D are oftenwhen measured using first generation immunometric as-
says, should be kept between 150 and 300 pg/mL in pa- necessary as plasma PTH levels decline and approach
the therapeutic target range, to diminish the risk of hy-tients with ESRD to maintain bone formation and turn-
over at relatively normal levels [1, 5, 66, 67]. The relatively percalcemia and to minimize the chances of developing
adynamic bone [16].higher normative values for plasma PTH in patients with
ESRD compared to persons with normal renal and para- New treatments such as calcimimetic agents offer the
prospect of controlling secondary hyperparathyroidismthyroid gland function are thought to reflect skeletal re-
sistance to the biological actions of PTH in renal failure. without relying on treatment with vitamin D or with the
use of much lower doses of vitamin D sterols. The widerIt is possible that N-terminally truncated, PTH-derived
peptides, perhaps by signaling through a C-PTH recep- availability of phosphate-binding agents that do not con-
tain calcium, such as sevelamer, and the possible intro-tor, contribute to this disturbance.
Nevertheless, plasma PTH levels that remain persis- duction of other calcium-free agents, such as lanthanum
carbonate and iron-containing compounds, may limit ex-tently higher than the recommended target range for
patients with ESRD are typically associated with bone posure to very large oral doses of calcium. By circum-
venting interventions that can separately affect PTH se-biopsy evidence of secondary hyperparathyroidism. In
contrast, PTH levels less than 150 pg/mL, particularly cretion, plasma PTH measurements in the future may
regain value as a useful indicator of bone turnover inthose below 100 pg/mL, usually indicate adynamic renal
osteodystrophy [1, 5, 6, 66]. Based upon published com- patients with renal failure. Until these therapeutic ap-
proaches are established and characterized, it may beparisons demonstrating approximately twofold differ-
ences between PTH values determined by first and sec- necessary to rely more frequently on bone histology to
ond generation immunometric assays, a target PTH effectively manage renal osteodystrophy in patients with
range of approximately 75 to 150 pg/mL as measured by ESRD.
second generation PTH assays would correspond to ex-
isting guidelines for the preferred concentration of PTH
CONCLUSIONin plasma for patients with ESRD. Although marked
The recent characterization of additional modifiers ofdisparities between results occur in some patients, the
bone metabolism provides further insight into mecha-physiological importance of these findings is uncertain
nisms to account for the development of certain types ofand the factors responsible for them are largely un-
renal bone disease. These developments are potentiallyknown. Despite commercial endorsements, there is little
important ones for the field of bone biology, and theyobjective evidence to support the use of estimates of the
offer expanded opportunities to better delineate the mo-concentration of PTH-derived peptide fragments in the
lecular mechanisms by which PTH and PTH-deriveddiagnosis or management of renal osteodystrophy. Bone
peptides modulate mineral metabolism and skeletal re-biopsy evidence of adynamic renal osteodystrophy is
modeling. Insufficient information is available, however,found in some patients whose plasma PTH levels exceed
to extend these concepts into the clinical setting, and it500 pg/mL as measured by first generation immuno-
is premature to apply these principles to the managementmetric PTH assays, but such individuals have often been
of patients with renal osteodystrophy. Further work istreated with active vitamin D sterols and oral calcium
required to adequately document the importance ofsupplements. Relatively low serum alkaline phosphatase
PTH-derived peptides and signaling through a C-PTHlevels may help to identify such cases [80].
receptor as key modulators of skeletal metabolism inDisturbances implicated as causes of adynamic bone
chronic renal failure.in ESRD include diabetes, aggressive treatment of sec-
New second generation immunometric PTH assaysondary hyperparathyroidism with vitamin D, the admin-
measure full-length biologically active PTH(1-84) exclu-istration of large oral doses of calcium, and hypercalce-
sively, and this feature distinguishes them from currentlymia. Further work is needed to determine whether these
available first generation immunometric PTH assays. Re-same variables influence the accumulation of N terminally-
sults provided by first generation immunometric PTHtruncated PTH-derived peptides in serum or plasma and,
assays will continue, however, to guide current manage-thus, account for wide disparities between first and sec-
ment decisions because they are supported by abundantond generation immunometric PTH assays in some
bone histology data. Whether second generation immu-patients with ESRD. High blood ionized calcium concen-
nometric PTH assays provide more reliable informationtrations affect the release and/or production of N termi-
for the initial diagnosis and/or longitudinal follow-up ofnally-truncated PTH-derived peptides, but the impact of
these changes on bone metabolism remains uncertain. patients with renal bone disease remains to be determined.
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in pediatric patients and young adults treated by hemodialysis inIndeed, the interpretation of serum or plasma PTH val-
a childrens hospital. J Am Soc Nephrol 12:1938–1946, 1993
ues obtained using second generation immunometric PTH 14. Hutchison AJ, Whitehouse RW, Boulton HF, et al: Correlation
assays in patients with ESRD depends largely upon their of bone histology with parathyroid hormone, vitamin D3, and radi-
ology in end-stage renal disease. Kidney Int 44:1071–1077, 1993correlation with first generation assays and only then by
15. Coburn JW, Salusky IB, Norris KC, Goodman WG: Oral andextrapolation to bone histology. Adequate supporting parenteral calcitriol for the management of end-stage renal disease.
bone biopsy data have yet to be reported with second Contrib Nephrol 90:166–182, 1991
16. Martin KJ, Gonzalez EA, Gellens M, et al: 19-Nor-1--25-dihy-generation immunometric PTH assays to guide their use.
droxyvitamin D2 (paricalcitol) safely and effectively reduces theIf measurements are done using second generation im- levels of intact parathyroid hormone in patients on hemodialysis.
munometric PTH assays in patients with ESRD, guide- J Am Soc Nephrol 9:1427–1432, 1998
17. Frazao JM, Elangovan L, Maung HM, et al: Intermittent doxer-lines for the interpretation of results relative to values
calciferol (1-hydroxyvitamin D2) therapy for secondary hyper-expected using first generation assays should be provided parathyroidism. Am J Kidney Dis 36:562–565, 2000
to avoid untoward diagnostic or therapeutic outcomes. 18. Monier-Faugere MC, Malluche HH: Calcitriol pulse therapy in
patients with end-stage renal failure. Curr Opin Nephrol Hypertens
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